B
Bruce L. Miller
Researcher at University of California, San Francisco
Publications - 1296
Citations - 135366
Bruce L. Miller is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Frontotemporal dementia & Dementia. The author has an hindex of 163, co-authored 1153 publications receiving 115975 citations. Previous affiliations of Bruce L. Miller include University of Southern California & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Clinical and Pathological Continuum of Multisystem TDP-43 Proteinopathies
Felix Geser,Maria Martinez-Lage,John L. Robinson,Kunihiro Uryu,Manuela Neumann,Nicholas J. Brandmeir,Sharon X. Xie,Linda K. Kwong,Lauren Elman,Leo McCluskey,Christopher M. Clark,Joe Malunda,Bruce L. Miller,Earl A. Zimmerman,Jiang Qian,Vivianna M. Van Deerlin,Murray Grossman,Virginia M.-Y. Lee,John Q. Trojanowski +18 more
TL;DR: Evidence of neuronal and glial TDP-43 pathology in all disease groups throughout the neuraxis is found, albeit with variations in the frequency, morphology, and distribution of T DP-43 lesions.
Journal ArticleDOI
Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector
Chengzhong Wang,Ramsey Najm,Qin Xu,Dah-Eun Jeong,David Walker,Maureen E. Balestra,Seo Yeon Yoon,Heidi Yuan,Gang Li,Zachary A. Miller,Bruce L. Miller,Mary J. Malloy,Yadong Huang +12 more
TL;DR: Human iPSC-derived neurons are generated from individuals with or without Alzheimer's disease carrying different APOE alleles and reveal a toxic, neuron-intrinsic gain of function of the ApoE4 variant that is a strong genetic risk factor for AD.
Journal ArticleDOI
Self awareness and personality change in dementia
TL;DR: This study operationalises research criteria for loss of insight in FTD, and shows that despite personality changes over time, patients with AD showed accurate self awareness in all personality dimensions except submissiveness and extraversion.
Journal ArticleDOI
Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial
Adam L. Boxer,Anthony E. Lang,Murray Grossman,David S. Knopman,Bruce L. Miller,Lon S. Schneider,Rachelle S. Doody,Andrew J. Lees,Lawrence I. Golbe,David R. Williams,Jean-Christophe Corvol,Albert C. Ludolph,David J. Burn,Stefan Lorenzl,Irene Litvan,Erik D. Roberson,Günter U. Höglinger,Mary Koestler,Clifford R. Jack,Viviana M. Van Deerlin,Christopher Randolph,Iryna Lobach,Hilary W. Heuer,Illana Gozes,Lesley Parker,Steve Whitaker,Joe Hirman,Alistair J Stewart,Michael Gold,Bruce H. Morimoto +29 more
TL;DR: Davunetide is not an effective treatment for PSP and clinical trials of disease-modifying treatment are feasible in patients with PSP and should be pursued with other promising tau-directed treatments.
Journal ArticleDOI
Clinical syndromes associated with posterior atrophy: early age at onset ad spectrum
Raffaella Migliaccio,Federica Agosta,Katya Rascovsky,Anna Karydas,Stephen J. Bonasera,Gil D. Rabinovici,Bruce L. Miller,Maria Luisa Gorno-Tempini,Maria Luisa Gorno-Tempini +8 more
TL;DR: Logopenic progressive aphasia and posterior cortical atrophy showed largely overlapping anatomic and biologic features with early age at onset of Alzheimer disease, suggesting that these clinical syndromes represent the spectrum of clinical manifestation of the nontypical form of Alzheimer Disease that presents at an early age.